ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
ResMed Inc

ResMed Inc (RMD)

252.86
2.92
(1.17%)
종가: 30 1월 6:00AM
252.86
0.00
( 0.00% )
시간외 거래: 6:15AM

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

가격
252.86
매수가
-
매도가
-
거래량
928,375
248.22 일간 변동폭 253.50
170.56 52주 범위 260.49
market_cap
전일 종가
249.94
개장가
249.67
최근 거래 시간
1
@
252.86
마지막 거래 시간
06:15:03
재정 규모
US$ 233,259,835
VWAP
251.2561
평균 볼륨(3m)
780,556
발행 주식
146,795,746
배당수익률
0.84%
주가수익률
36.36
주당순이익(EPS)
6.95
매출
4.69B
순이익
1.02B

ResMed Inc 정보

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting ... ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting. 더 보기

섹터
Surgical,med Instr,apparatus
산업
Surgical,med Instr,apparatus
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
ResMed Inc is listed in the Surgical,med Instr,apparatus sector of the 뉴욕 증권거래소 with ticker RMD. The last closing price for ResMed was US$249.94. Over the last year, ResMed shares have traded in a share price range of US$ 170.56 to US$ 260.49.

ResMed currently has 146,795,746 shares in issue. The market capitalisation of ResMed is US$36.69 billion. ResMed has a price to earnings ratio (PE ratio) of 36.36.

ResMed (RMD) 옵션 플로우 요약

전체 흐름

강세

순 프리미엄

483k

Calls / Puts

250.00%

매수 / 매도

133.33%

OTM / ITM

133.33%

Sweeps 비율

28.57%

RMD 최신 뉴스

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on...

ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
16.792.75937741293246.07258.7243.23921057251.13752118CS
422.9739.99317055771229.887258.7226.6601826419239.86145719CS
125.12.05844365515247.76258.7224.51780556240.60780834CS
2652.7426.3541874875200.12260.49198.6931133238.29562295CS
5262.9133.1192419058189.95260.49170.56993172215.94972279CS
15631.0614.003606853221.8262.38132.24854343202.1256616CS
26087.8653.2484848485165301.34108.85756357202.2866448CS

RMD - Frequently Asked Questions (FAQ)

What is the current ResMed share price?
The current share price of ResMed is US$ 252.86
How many ResMed shares are in issue?
ResMed has 146,795,746 shares in issue
What is the market cap of ResMed?
The market capitalisation of ResMed is USD 36.69B
What is the 1 year trading range for ResMed share price?
ResMed has traded in the range of US$ 170.56 to US$ 260.49 during the past year
What is the PE ratio of ResMed?
The price to earnings ratio of ResMed is 36.36
What is the cash to sales ratio of ResMed?
The cash to sales ratio of ResMed is 7.92
What is the reporting currency for ResMed?
ResMed reports financial results in USD
What is the latest annual turnover for ResMed?
The latest annual turnover of ResMed is USD 4.69B
What is the latest annual profit for ResMed?
The latest annual profit of ResMed is USD 1.02B
What is the registered address of ResMed?
The registered address for ResMed is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the ResMed website address?
The website address for ResMed is www.resmed.com
Which industry sector does ResMed operate in?
ResMed operates in the SURGICAL,MED INSTR,APPARATUS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
IBMInternational Business Machines Corp
US$ 254.39
(11.27%)
396.86k
CALXCalix Inc
US$ 41.00
(11.20%)
5.4k
SPRUSpruce Power Holding Corporation
US$ 2.80
(6.46%)
100
UIUbiquiti Inc
US$ 409.99
(6.34%)
546
CCRDCoreCard Corporation
US$ 24.0571
(5.70%)
700
BFLYButterfly Network Inc
US$ 3.15
(-10.26%)
150.55k
NOWServiceNow Inc
US$ 1,030.00
(-9.94%)
61.88k
WHRWhirlpool Corp
US$ 117.00
(-9.85%)
33.21k
OSCROscar Health Inc
US$ 16.11
(-3.42%)
6.08k
DMDesktop Metal Inc
US$ 2.10
(-3.23%)
513
LUMNLumen Technologies Inc
US$ 5.01
(0.00%)
11.36M
CCLCarnival Corp
US$ 27.91
(0.00%)
774.32k
CAHCardinal Health Inc
US$ 127.76
(0.00%)
703.39k
FGSNF&G Annuities and Life Inc
US$ 24.88
(0.04%)
566.83k
SOSouthern Co
US$ 82.83
(0.00%)
514.39k

RMD Discussion

게시물 보기
whytestocks whytestocks 4 년 전
News; $RMD ResMed (RMD) Q1 2021 Earnings Call Transcript

Image source: The Motley Fool. ResMed (NYSE: RMD) Q1 2021 Earnings Call Oct 29, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: ResMed (RMD) Q1 2021 Earnings Call Transcript

Find out more RMD - ResMed (RMD) Q1 2021 Earnings Call Transcript
👍️0
TheFinalCD TheFinalCD 5 년 전
RMD was just on Cramers MAd mONEy tonight

👍️0
whytestocks whytestocks 5 년 전
News: $RMD Why ResMed Stock Is Shooting Higher Today

After management reported fiscal 2020 first-quarter results , shares of ResMed (NYSE: RMD) , a medical device maker focused on sleep-disorder breathing, rose 12% as of 12:00 p.m. EDT on Friday. The headline numbers from the period were great: Traders sent the share price to a new all-time ...

In case you are interested RMD - Why ResMed Stock Is Shooting Higher Today
👍️0
whytestocks whytestocks 5 년 전
News: $RMD How ResMed Blew Past Expectations With Its Q1 Results

Despite a horrible start, 2019 has turned out to be a reasonably good year so far for ResMed (NYSE: RMD) . The healthcare company has consistently beaten Wall Street earnings estimates in recent quarters and delivered solid growth. ResMed announced its fiscal 2020 first-quarter results after...

Got this from RMD - How ResMed Blew Past Expectations With Its Q1 Results
👍️0
ming1234 ming1234 6 년 전
100+ tomorrow.
👍️0
crudeoil24 crudeoil24 7 년 전
100
👍️0
ValueInvestor15 ValueInvestor15 8 년 전
ResMed $RMD has little Margin of Safety for value investors before earnings Monday:

Fair Value Analysis
👍️0
phrantic phrantic 14 년 전
Medical Device Maker Delivers Wake-Up Call
MANUFACTURING: ResMed, Major Rival Team Up to Educate Clinicians About Sleep Disorders

In addition to announcing record revenues recently, ResMed is teaming up with a major competitor to educate the medical community in a $1 million campaign to help reach millions of undiagnosed Americans with sleeping disorders, especially sleep apnea.

Company officials said Sept. 30 that the campaign with Respironics, another device maker, and Cephalon, a drug company, is a wake-up call to action for a public health threat that the U.S. Department of Health & Human Services said results in an estimated $16 billion annually in medical costs, not including costs associated with lost work time.

http://www.sdbj.com/news/2010/oct/11/medical-device-maker-delivers-wake-call/
👍️0
Rckhnd Rckhnd 14 년 전
SYDNEY (Dow Jones)--Sleep disorder device company ResMed Inc. (RMD.AU) has agreed to revise its internal fair-trading checks following an investigation of price-fixing by Australia's competition regulator.

The Australian Competition and Consumer Commission said Tuesday it had investigated the company over whether it was telling accredited retailers that it would stop supplying its products if they sold them at less than a price specified by ResMed, a practice known as retail price maintenance.

"The ACCC is concerned that between March and June 2009 ResMed is likely to have engaged in retail price maintenance," the ACCC said in a statement.

ResMed has accepted a court-enforceable undertaking to write to its accredited retailers telling them they are free to set their own prices, and to amend its compliance program for Australian trade practices law, the ACCC said.

ResMed did not immediately respond to a call for comment.

-By David Fickling, Dow Jones Newswires; +61 2 8272 4689; david.fickling@dowjones.com

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/access/al?rnd=QNuS73vTbwGle8%2BC70zpfA%3D%3D. You can use this link on the day this article is published and the following day.

(END) Dow Jones Newswires
👍️0
Rckhnd Rckhnd 14 년 전
ResMed Inc. (NYSE: RMD) announced today that its two-for-one stock split of the company's outstanding shares of common stock, payable in the form of a 100% stock dividend was completed on August 30, 2010. The new total shares outstanding doubled to 151,388,240 shares, excluding shares held as treasury stock. The closing price of the company's common stock on the New York Stock Exchange on August 30, 2010 was $60.38. On a split-adjusted basis, the company's closing stock price on August 30, 2010 would have been $30.19. The company's total market capitalization as of August 30, 2010 was approximately $4.6 billion on that date.
👍️0
Rckhnd Rckhnd 14 년 전
Yes! 2:1 split has happened!
Now just waiting for those free shares to show up!
👍️0
Rckhnd Rckhnd 14 년 전
Steady climb pre-split. Financials decent. Should resume upward trend after split.
👍️0
Rckhnd Rckhnd 14 년 전
SYDNEY, Aug 12, 2010 /PRNewswire via COMTEX/ -- ResMed, Inc. (NYSE: RMD), (ASX:
RMD) announced today that the company has been granted a waiver of rules 13.9.4
and 13.9.9 of the Australian Stock Exchange Settlement Operating Rules, in
connection with the stock split announced to the Market on 6 August 2010.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100203/RESMEDLOGO)

As advised in the Company's 6 August announcement:

Stockholders of record on the New York Stock Exchange at the close of trading on
August 17, 2010 will receive one additional share of common stock for each share
held on that date. The common stock will be distributed to shareholders on or
about August 30, 2010, by ResMed's NYSE transfer agent, American Stock Transfer
and Trust Company, LLC. The common stock is expected to begin trading on a
post-split basis on the NYSE beginning on August 31, 2010, or one day following
the distribution date.

Holders of CHESS Depositary Interests (CDIs) on the Australian Stock Exchange
will also receive a bonus issue of one additional CDI for every CDI held on the
ASX record date of August 18, 2010. Unlike the shares on the NYSE, the existing
CDIs will be quoted on an "ex-bonus" basis on August 12, 2010 on the ASX (ASX:
RMD), and bonus CDI's will be quoted on a deferred settlement basis (ASX:
RMDBN). The bonus CDIs will be distributed by ResMed's ASX share registry,
Computershare Limited, on or about August 31, 2010, and normal trading will
begin on the following day.

Due to the difference in market practice between the NYSE and ASX, ResMed
applied for and has been granted a waiver of rules 13.9.4 and 13.9.9 of the ASX
Settlement Operating Rules, allowing it to defer the processing of conversions
(transmutations) between its Common Stock and CDI registers that are lodged in
the period from and including 12 August 2010 up to and including 31 August 2010.
Therefore, no conversions (transmutations) will be processed during this time.
Processing of conversions will re-commence on 1 September 2010.

About ResMed

ResMed is a leading developer, manufacturer and distributor of medical equipment
for the treatment and management of sleep-disordered breathing and other
respiratory disorders. The company is dedicated to developing innovative
products to improve the lives of those who suffer from these conditions and to
increasing awareness among patients and healthcare professionals of the
potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Constance Bienfait at ResMed,
Inc., San Diego, on (+ 1 858-836-5971), or Brett Sandercock at ResMed Limited,
Sydney, on (+61 2) 8884-2090; or by visiting the Company's multilingual Web site
at www.resmed.com.

SOURCE ResMed, Inc.
👍️0
Rckhnd Rckhnd 14 년 전
Chart



Looking forward to the split!!




👍️0
Rckhnd Rckhnd 14 년 전
2:1 stock split

Australian sleep management company RESMED INC (ASX:RMD) on Friday booked record revenue and income for the 2010 full financial year and announced a two-for-one stock split. ResMed said that for the year ended June 30, 2010, income from operations was US$240.4 million, and net income was US$190.1 million, an increase of 26 per cent and 30 per cent respectively, compared to the 2009 full financial year.

* Annual revenue in 2010 was US$1.1 billion, up 19 per cent (or 17 per cent on a constant currency basis) over 2009.

* ResMed also announced on Friday that its board of directors had approved a two-for-one stock split of the company's outstanding shares of common stock, payable in the form of a 100 per cent stock dividend.
👍️0